Study ID: Merck MK-3475-689 HNSCC


A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Title: A Clinical Trial for Locally Advanced Head and Neck Cancer Description: You are participating in a clinical trial studying an investigational immunotherapy, pembrolizumab. This trial is enrolling patients who are 18 years of age or older who have a new diagnosis of head and neck cancer. You will get either the research study drug, pembrolizumab, in combination with surgery and radiation therapy (with or without chemotherapy), or surgery in combination with radiation therapy (with or without chemotherapy).
Sioux Falls Region
Principal Investigator:
W. Chad Spanos, MD
Head and Neck
Phase III
Active - Open to Accrual